Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway

Riluzole is approved by the FDA as an amyotrophic lateral sclerosis (ALS) drug. Previous studies showed that treatment with riluzole suppressed the proliferation of many cancer cells. However, little is known about its effects on nasopharyngeal carcinoma (NPC) and its molecular mode of action. In th...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Lu, Wu, Cheng, Ming, Jun, Nie, Xin, Guo, Ergang, Zhang, Wei, Hu, Guoqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097961/
https://www.ncbi.nlm.nih.gov/pubmed/32231713
http://dx.doi.org/10.7150/jca.41217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097961/
https://www.ncbi.nlm.nih.gov/pubmed/32231713
http://dx.doi.org/10.7150/jca.41217

Ejemplares similares